FDA Week - 06/21/2019

Gottlieb Defends Pfizer, Says Drug Makers Not Obliged To Explore Signals

By David Roza / June 14, 2019 at 3:24 PM
Former FDA Commissioner Scott Gottlieb defended drug maker Pfizer’s choice to not investigate signals that its anti-inflammatory drug Enbrel appeared to reduce the risk of Alzheimer’s, as the Washington Post reported on June 4. In a discussion hosted by the Post on Tuesday (June 11), Gottlieb said the Pfizer story opens up a wider question about whether drug makers are obliged to investigate or publish any kind of potential treatment signal that researchers encounter. “I think the answer...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.